FibroBiologics, Inc. Common Stock (FBLG) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
455 East Medical Center Boulevard
Houston, DE 77598
United States of America (the)
Phone
281 651 5150
Sector
Healthcare
Industry
Biotechnology
Employees
13
First IPO Date
February 01, 2024
| Name | Title | Pay | Year Born |
| Peter O'Heeron | Founder, Chairperson & Chief Executive Officer | 657,364 | 1964 |
| Ruben A. Garcia | General Counsel | 456,240 | 1977 |
| Hamid Khoja | Chief Scientific Officer | 483,510 | 1970 |
| Jason D. Davis | Chief Financial Officer | 509,273 | 1972 |
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.